E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
DVT and PE are part of the same disease that can be defined Venous Thromboembolism (VTE). Treatment of the acute phases is well established: LMWH during the first days and OAT for 3-12 months. After cessation of OAT, recurrence venous thromboembolism (VTE) often occurs, with an estimated early rate of 6-9%. Defibrotide possesses antithrombotic, anti-ischemic and thrombolytic properties, without anti-coagulant effects. Defibrotide after cessation of OAT could reduce the recurrence rate of VTE |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10051055 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess whether oral defibrotide treatment may offer a 50% increase in the protection against the recurrenceof DVT, and further confirm its safety in long term administration. |
|
E.2.2 | Secondary objectives of the trial |
To assess the effect of oral defibrotide treatment on other thrombo-embolic events, venous and arterial, and VTE related cardiovascular mortality, objectively assessed, during treatment, in comparison with placebo. To evaluate the changes in in the patient´s assessment of the Quality of Life, and to confirm the long term safety of oral defibrotide treatment. To evaluate the acceptance of treatment both by the patient and by the investigator. |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
Adult male or female outpatients, age 18-75 years. Have suffered from a documented recent episode of DVT (within 1 year of the screening visit), irrespective whether the DVT episode was provoked or non provoked, first episode or recurrence, OAT must be ended since 30 days on the date of the screening visit. |
|
E.4 | Principal exclusion criteria |
Patients who still present signs of active DVT at color flow Doppler scanning, Female patients in child bearing age not using adequate contraceptive method, or using oral hormonal contraception, obesity as defined by a Body Mass Index (BMI) 32 kg/m2 (see appendix 28.5), severe alteration of coagulation parameters, clinically relevant kidney function impairment (serum creatinine exceeding 150% of the upper normal range), clinically relevant impairment of liver function (serum enzymes and/or bilirubin exceeding 150% of the upper normal range), subjects who receive concomitant fibrinolytic drugs and/or platelet aggregation inhibitors, ASA, NSAIDS, that cannot be withdrawn without prejudice to the health, subjects that receive veno-active drugs (e.g.: diosmine, rutosides), subjects presentingwith congestive hearth failure (NYHA clas III and IV), (see appendix 28.6). Patients suffering from peripheral obstructive arterial disease. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Time to first episode of recurrence of DVT, objectively confirmed, during treatment, in comparison with placebo group. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Crinos SpA reserves the right to discontinue the study at any time, for internal reasons, for lack of efficacy or safety reasons. Crinos may discontinue a study site, because of significant deviations from the study protocol, or due to insurmountable difficulties experienced in running the study at that center or unacceptable delays in obtaining the ethical or administrative authorisations |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 38 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 38 |